Champions Oncology (CSBR) Other Working Capital Changes (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Other Working Capital Changes of -$1.2 million for Q2 2026, down 125.88% year-over-year from $4.5 million in Q2 2025, and up 50.0% quarter-over-quarter from -$2.3 million in Q1 2026.
Champions Oncology (CSBR) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Champions Oncology's Other Working Capital Changes history runs 12 years deep, the most recent figure standing at -$1.2 million for Q2 2026.
- In Q2 2026, Other Working Capital Changes fell 125.88% year-over-year to -$1.2 million; the TTM figure through Apr 2026 stood at -$6.6 million (down 297.52% YoY), while the FY2026 annual figure was -$6.6 million, down 297.52% from the prior year.
- Other Working Capital Changes for Q2 2026 stood at -$1.2 million, up from -$2.3 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $4.4 million in Q2 2022, with the low at -$560000.0 in Q4 2022.
- The 5-year median for Other Working Capital Changes is -$75000.0 (2022), against an average of $245333.3.
- Peak annual rise in Other Working Capital Changes reached 1549.04% in 2025, while the deepest fall reached 2172.83% in 2025.
- Champions Oncology's Other Working Capital Changes stood at -$325000.0 in 2022, then soared by 433.85% to $1.1 million in 2023, then tumbled by 108.48% to -$92000.0 in 2024, then plunged by 2172.83% to -$2.1 million in 2025, then surged by 44.05% to -$1.2 million in 2026.
- Business Quant data shows CSBR's Other Working Capital Changes at -$1.2 million in Q2 2026, -$2.3 million in Q1 2026, and -$2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 179,000.00 |
| Apr 30, 2026 | 179,000.00 |
| Apr 30, 2026 | 179,000.00 |
| Jan 31, 2026 | -287,000.00 |
| Jan 31, 2026 | -287,000.00 |
| Jan 31, 2026 | -287,000.00 |
| Oct 31, 2025 | 62,000.00 |
| Oct 31, 2025 | 62,000.00 |
| Oct 31, 2025 | 62,000.00 |
| Jul 31, 2025 | -154,000.00 |
| Jul 31, 2025 | -154,000.00 |
| Jul 31, 2025 | -154,000.00 |
| Apr 30, 2025 | 638,000.00 |
| Apr 30, 2025 | 638,000.00 |
| Apr 30, 2025 | 638,000.00 |
| Jan 31, 2025 | -147,000.00 |
| Jan 31, 2025 | -147,000.00 |
| Jan 31, 2025 | -147,000.00 |
| Oct 31, 2024 | -394,000.00 |
| Oct 31, 2024 | -394,000.00 |